Stoichiometric antibody-polymer-drug conjugate for effective low-dose treatment of breast cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389013%3A_____%2F25%3A00641227" target="_blank" >RIV/61389013:_____/25:00641227 - isvavai.cz</a>
Result on the web
<a href="https://pubs.acs.org/doi/10.1021/acs.biomac.5c00598" target="_blank" >https://pubs.acs.org/doi/10.1021/acs.biomac.5c00598</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1021/acs.biomac.5c00598" target="_blank" >10.1021/acs.biomac.5c00598</a>
Alternative languages
Result language
angličtina
Original language name
Stoichiometric antibody-polymer-drug conjugate for effective low-dose treatment of breast cancer
Original language description
In the past two decades, antibody–drug conjugates (ADCs) have emerged as highly effective targeted therapeutics against cancers. One current path to improve ADCs is to increase the amount of cytotoxic payload delivered to cancer cells by conjugating antibodies with a soluble polymer bearing several drug molecules. However, this approach is challenging due to the high molecular weight of the polymer and the need to strictly control the degree of conjugation to maintain favorable pharmacokinetic and binding profiles. Here, we build from the recent development brought to our automated stoichiometric conjugation device to tackle this challenge. We produced a new format of ADC-like targeted therapy: monoconjugated Antibody–Polymer–Drug Conjugates (APDCs) with enzyme-cleavable linkers, designed to achieve selective delivery of the cytotoxic MMAE to HER2+ cancer cells. We showed the selectivity of our conjugates for HER2+ over HER2– cells in vitro and demonstrated their efficiency in vivo in a SKBR-3-xenografted mouse (NOD-SCID) model.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10404 - Polymer science
Result continuities
Project
<a href="/en/project/LX22NPO5102" target="_blank" >LX22NPO5102: National institute for cancer research</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Biomacromolecules
ISSN
1525-7797
e-ISSN
1526-4602
Volume of the periodical
26
Issue of the periodical within the volume
11
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
7309-7318
UT code for WoS article
001592239700001
EID of the result in the Scopus database
2-s2.0-105021118665